Evaluation of Zotarolimus Eluting Stent at 3 Months Using Optical Coherence Tomography

NCT ID: NCT00815139

Last Updated: 2008-12-29

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 30 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2008-02-29

Brief Summary

Neointimal coverage over stent strut is important for preventing the stent thrombosis. But, there is no data for the duration of complete formation of neointima om zotarolimus eluting stent (ZES). Previously the investigational observational data at 9 months showed most of stent strut was covered with neointima. Therefore, the investigators investigated the evaluation of neointimal coverage on 3 months after ZES implantation using novel OCT system, which is powerful intravascular imaging system having the higher resolution power.

Detailed Description

Stent thrombosis is current main issue after introduction of drug-eluting stents and theoretically dual antiplatelet therapy should be continued to prevent the stent thrombosis until complete reendothelization. Currently, AHA/ACC guideline recommend dual antiplatelet should continue at least 3 months in Sirolimus eluting stent (SES) and 6 months in paclitaxel eluting stent (PES), but if possible, suggest to use until 12 months.

Zotarolimus (Endeavor®) eluting stent (ZES) have been recently introduced and focused on reducing concern of safety through the biocompatible polymer and rapid drug elution. ENDEAVOR II trial showed a 0.5 per cent rate of stent thrombosis at 30 days - with no late thrombosis beyond 30 days and no late stent malapposition. In the long term follow up data of Endeavor stent, the two-year clinical results of ENDEAVOR I were impressive, with a low TVF and MACE rate (2% and 3% respectively) with the absence of reported thromboses after day 14. These results speak, especially the lack of stent thrombosis after 14 days, reflect very well on the performance and safety of the ZES.

But, there has been no guideline for the duration of dual antiplatelet therapy in ZES although shorter duration of dual antiplatelet therapy could be safe compared to previous drug-eluting stents. Also, there is no data how long duration might be taken in completion of reendothelialization after ZES implantation in living patients. The most powerful histological predictor of stent thrombosis was endothelial coverage. The best morphometric predictor of LST was the ratio of uncovered to total stent struts. Because the presence of endothelization is not available in in vivo situation and endothelialization is reported to be associated with neointimal coverage of stent, the detection of neointima after stent implantation could be the main issue to predict the stent thrombosis. Recent data in SES using optical coherence tomography (OCT) reported neointimal coverage over a SES at 3-month follow-up is incomplete. The rates of exposed struts and exposed struts with malapposition were 15% and 6%, respectively. These were more frequent in patients with acute coronary syndrome (ACS) than in those with non-ACS (18% vs 13%, p <0.0001; 8% vs 5%, p <0.005, respectively).

Although neointimal coverage could be completely in early period after ZES implantation, there is no data for this finding. Therefore, we investigate the evaluation of neointimal coverage on 3 months after ZES implantation using novel OCT system, which is powerful intravascular imaging system having the higher resolution power. This study may provide adequate information on the safety of discontinuation of dual antiplatelet therapy for patients in clinical situations.

Conditions

Coronary Artery Disease

Keywords

Coronary artery disease, stent

Study Design

• Observational Model Type: CASE_ONLY
• Study Time Perspective: PROSPECTIVE

Study Groups

ZES group

Groups who were treated with zotarolimus eluting stent

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Significant coronary de novo lesion ( > 70% by quantitative angiographic analysis)
• Patients with stable or acute coronary syndrome considered for coronary revascularization.
• Non-emergent conditions
• Reference vessel diameter of 2.75 to 4.0 mm by operator assessment

Exclusion Criteria

• The criteria for exclusion were contraindication to anti-platelet agents
• ST elevation MI requiring primary PCI
• Proximal lesion within 15 mm from ostium
• Prior insertion of other DES in any vessel
• Creatinine level more than 2.0mg/dL or ESRD
• Severe hepatic dysfunction (more than 3 times normal reference values)
• Pregnant women or women with potential childbearing
• Life expectancy less than 1 year
• Complex lesion morphologies (aorto-ostial, bifurcation with >2.0 mm side branch, unprotected Left main, thrombus, severe calcification, chronic total occlusion)
• Target lesion is vein graft lesion
• Reference vessel <2.5 mm or >4.0 mm diameter by visual estimation
• Long lesion that require more than two stents

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Yonsei University

OTHER

Sponsor Role: lead

Responsible Party

Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei Univerisity

Principal Investigators

Yangsoo Jang, MD, Ph D

Role: PRINCIPAL_INVESTIGATOR

Division of Cardiology, Cardiovascular Hospital, Yonsei University

Locations

Division of Cardiology, Cardiovascular Hospital, Yonsei University

Seoul, , South Korea

Countries

South Korea

References

Kim JS, Jang IK, Fan C, Kim TH, Kim JS, Park SM, Choi EY, Lee SH, Ko YG, Choi D, Hong MK, Jang Y. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial. JACC Cardiovasc Interv. 2009 Dec;2(12):1240-7. doi: 10.1016/j.jcin.2009.10.006.

Reference Type: DERIVED

PMID: 20129551 (View on PubMed)

Other Identifiers

4-2007-0409

Identifier Type: -

Identifier Source: org_study_id